VRCA Verrica Pharmaceuticals Inc.

14
-0.47  -3%
Previous Close 14.47
Open 14.65
Price To Book 4.68
Market Cap 360,378,158
Shares 25,741,297
Volume 82,340
Short Ratio
Av. Daily Volume 40,350

NewsSee all news

  1. Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

    WEST CHESTER, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  2. Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference

    WEST CHESTER, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced September 16, 2019.
VP-102
Molluscum contagiosum
Phase 2 data noted 51% of patients noted complete clearance of warts - June 26, 2019.
VP-102
Common warts
Phase 2 data due 2H 2020
VP-102
Genital warts

Latest News

  1. Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

    WEST CHESTER, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  2. Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference

    WEST CHESTER, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that